Art. -Nr.: HY-N5120

Dihydrowithaferin A

(Synonyms: 2,3-Dihydrowithaferin A)

Kundenbewertung

Based on 1 Customer Validation

Dihydrowithaferin A (2, 3-dihydrowithaferin A) is a withanolide isolated from Withania somnifera. Dihydrowithaferin A is active against acetylcholinesterase (AChE).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.72%
CAS. Nr.: 5589-41-3
Formel: C₂₈H₄₀O₆
Molecular Weight:472.61

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Dihydrowithaferin A Chemical Structure

CAS. Nr.: 5589-41-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Dihydrowithaferin A (2, 3-dihydrowithaferin A) is a withanolide isolated from Withania somnifera. Dihydrowithaferin A is active against acetylcholinesterase (AChE)^[1].

IC₅₀ & Target

AChE

Alle Cholinesterase (ChE) Isoform-spezifische Produkte anzeigen :

AChE
BChE

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	17.2 μM Compound: 10	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
A549	IC₅₀	19.7 μM Compound: 38	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
A549	IC₅₀	33.5 μM Compound: 10	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
A549	IC₅₀	33.5 μM Compound: 38	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
B16-F10	IC₅₀	>10 μM Compound: 20	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTS assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTS assay	[PMID: 22098611]
C3H 10T1/2	IC₅₀	>25 μM Compound: 4	Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by FMCA Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by FMCA	[PMID: 26169123]
DU-145	IC₅₀	>25 μM Compound: 4	Cytotoxicity against human DU145 cells after 24 hrs by FMCA Cytotoxicity against human DU145 cells after 24 hrs by FMCA	[PMID: 26169123]
HaCaT	IC₅₀	14.8 μM Compound: 4	Inhibition of hedgehog/GLI1-mediated transcriptional activity in human HaCaT cells after 12 hrs by luciferase assay Inhibition of hedgehog/GLI1-mediated transcriptional activity in human HaCaT cells after 12 hrs by luciferase assay	[PMID: 26169123]
HeLa	IC₅₀	19.3 μM Compound: 10	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
HeLa	IC₅₀	28.9 μM Compound: 10	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
HeLa	IC₅₀	28.9 μM Compound: 38	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
HeLa	IC₅₀	32.2 μM Compound: 38	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	>25 μM Compound: 4	Cytotoxicity against human MCF7 cells after 24 hrs by FMCA Cytotoxicity against human MCF7 cells after 24 hrs by FMCA	[PMID: 26169123]
MCF7	IC₅₀	12.2 μM Compound: 38	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	14.4 μM Compound: 10	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
MCF7	IC₅₀	14.4 μM Compound: 38	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	5.4 μM Compound: 10	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
NCI-H929	IC₅₀	>10 μM Compound: 20	Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay	[PMID: 24625088]
PANC-1	IC₅₀	>25 μM Compound: 4	Cytotoxicity against human PANC1 cells after 24 hrs by FMCA Cytotoxicity against human PANC1 cells after 24 hrs by FMCA	[PMID: 26169123]
SK-MEL-28	IC₅₀	>10 μM Compound: 20	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay	[PMID: 22098611]
Vero	IC₅₀	15.5 μM Compound: 10	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
Vero	IC₅₀	15.5 μM Compound: 38	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Vero	IC₅₀	24.2 μM Compound: 38	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Vero	IC₅₀	9 μM Compound: 10	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]

Chemical Information

CAS. Nr. 5589-41-3
Appearance Solid
Molecular Weight 472.61
Formel C₂₈H₄₀O₆
Color White to off-white
SMILES

C[C@]12[C@@]3([C@H](CCC2=O)O)[C@@H](C[C@]4([H])[C@]1([H])CC[C@@]5(C)[C@@]4([H])CC[C@]5([H])[C@@H]([C@@](O6)([H])CC(C)=C(CO)C6=O)C)O3
Synonyms

2,3-Dihydrowithaferin A
Structure Classification
- Steroids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (105.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1159 mL

10.5795 mL

21.1591 mL

5 mM

0.4232 mL

2.1159 mL

4.2318 mL

10 mM

0.2116 mL

1.0580 mL

2.1159 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (2.64 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (2.64 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (2.64 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Choudhary MI, et al. Cholinesterase inhibiting withanolides from Withania somnifera. Chem Pharm Bull (Tokyo). 2004 Nov;52(11):1358-61. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1159 mL	10.5795 mL	21.1591 mL	52.8977 mL
	5 mM	0.4232 mL	2.1159 mL	4.2318 mL	10.5795 mL
	10 mM	0.2116 mL	1.0580 mL	2.1159 mL	5.2898 mL
	15 mM	0.1411 mL	0.7053 mL	1.4106 mL	3.5265 mL
	20 mM	0.1058 mL	0.5290 mL	1.0580 mL	2.6449 mL
	25 mM	0.0846 mL	0.4232 mL	0.8464 mL	2.1159 mL
	30 mM	0.0705 mL	0.3527 mL	0.7053 mL	1.7633 mL
	40 mM	0.0529 mL	0.2645 mL	0.5290 mL	1.3224 mL
	50 mM	0.0423 mL	0.2116 mL	0.4232 mL	1.0580 mL
	60 mM	0.0353 mL	0.1763 mL	0.3527 mL	0.8816 mL
	80 mM	0.0264 mL	0.1322 mL	0.2645 mL	0.6612 mL
	100 mM	0.0212 mL	0.1058 mL	0.2116 mL	0.5290 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dihydrowithaferin A

Neuronal Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Covalent Screening Library

Traditional Chinese Medicine Active Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Membrane Protein-targeted Compound Library

Cysteine Targeted Covalent Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Alle Cholinesterase (ChE) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dihydrowithaferin A

Neuronal Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Covalent Screening Library

Traditional Chinese Medicine Active Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Membrane Protein-targeted Compound Library

Cysteine Targeted Covalent Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Alle Cholinesterase (ChE) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dihydrowithaferin A Related Classifications

HY-N5120 Related Classifications